Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Mallinckrodt
Merck
McKinsey
Colorcon

Last Updated: June 28, 2022

KINEVAC Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Kinevac patents expire, and when can generic versions of Kinevac launch?

Kinevac is a drug marketed by Bracco and is included in one NDA. There is one patent protecting this drug.

This drug has ten patent family members in eight countries.

The generic ingredient in KINEVAC is sincalide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sincalide profile page.

DrugPatentWatch® Generic Entry Outlook for Kinevac

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 16, 2022. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Drug patent expirations by year for KINEVAC
Drug Prices for KINEVAC

See drug prices for KINEVAC

DrugPatentWatch® Estimated Generic Entry Opportunity Date for KINEVAC
Generic Entry Date for KINEVAC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INJECTION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for KINEVAC

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Penn State UniversityN/A
Memorial Health University Medical CenterN/A
Temple UniversityN/A

See all KINEVAC clinical trials

Pharmacology for KINEVAC
Anatomical Therapeutic Chemical (ATC) Classes for KINEVAC

US Patents and Regulatory Information for KINEVAC

KINEVAC is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of KINEVAC is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting KINEVAC

Sincalide formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco KINEVAC sincalide INJECTABLE;INJECTION 017697-001 Approved Prior to Jan 1, 1982 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for KINEVAC

When does loss-of-exclusivity occur for KINEVAC?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 03304382
Estimated Expiration: See Plans and Pricing

Austria

Patent: 2647
Estimated Expiration: See Plans and Pricing

Canada

Patent: 03982
Estimated Expiration: See Plans and Pricing

China

Patent: 56557
Estimated Expiration: See Plans and Pricing

Patent: 0374154
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 31305
Estimated Expiration: See Plans and Pricing

Germany

Patent: 336509
Estimated Expiration: See Plans and Pricing

Japan

Patent: 51993
Estimated Expiration: See Plans and Pricing

Patent: 06515321
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KINEVAC around the world.

Country Patent Number Title Estimated Expiration
Japan 4751993 See Plans and Pricing
China 100374154 See Plans and Pricing
France 2007810 See Plans and Pricing
Canada 2503982 FORMULATIONS A BASE DE SINCALIDE (SINCALIDE FORMULATIONS) See Plans and Pricing
Switzerland 517702 Procédé de préparation de nouveaux peptides See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Harvard Business School
McKinsey
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.